{
    "clinical_study": {
        "@rank": "92391", 
        "acronym": "ULIIS", 
        "arm_group": {
            "arm_group_label": "Contrast-enhanced intraoperative ultrasound", 
            "arm_group_type": "Other", 
            "description": "Contrast-enhanced intraoperative ultrasound"
        }, 
        "brief_summary": {
            "textblock": "Hypothesis: Use of contrast ultrasound showed interesting results, which can increase\n      ultrasonography sensitivity performed during surgery in the evaluation of operable liver\n      metastases.\n\n      This study is a two-stage phase II multicenter study (Simon's two-stage)."
        }, 
        "brief_title": "Ultrasound Liver Intraoperative Imaging With SonoVue\u00ae", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Metastases From Colorectal Primary Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Liver Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Hypothesis: Use of contrast ultrasound showed interesting results, which can increase\n      ultrasonography sensitivity performed during surgery in the evaluation of operable liver\n      metastases.\n\n      This study is a two-stage phase II multicenter study (Simon's two-stage)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient with histological proven colorectal cancer.\n\n          2. Operable liver metastases according to preoperative imagery. Operability is the\n             possibility of treatment by resection and/or local destruction (radiofrequency,\n             cryotherapy\u2026).\n\n          3. Patient treated or not with preoperative chemotherapy.\n\n          4. With or without extra-hepatic metastases.\n\n          5. Age \u2265 18 years.\n\n          6. Radiological assessment by CT and MRI liver and TEPscan within six weeks before\n             surgery.\n\n          7. Patient affiliated to the Social Security system.\n\n          8. Signed informed consent.\n\n        Exclusion Criteria:\n\n          1. Known hypersensitivity to sulfur hexafluoride or another component of SonoVue\u00ae.\n\n          2. Patients with recent acute coronary syndrome or suffering from unstable ischemic\n             heart disease, especially: evolving myocardial infarction, unstable angina during the\n             last 7 days, recent coronary intervention or another factor suggesting clinical\n             instability, acute heart failure, class III or IV heart failure, severe arrhythmias.\n\n          3. Patients with right-to-left shunt, severe pulmonary arterial hypertension,\n             uncontrolled systemic hypertension, as patients suffering from respiratory distress\n             syndrome.\n\n          4. Pregnant and lactating women.\n\n          5. Patients with contraindication for a CT scan, a MRI or a TEP with contrast.\n\n          6. Patients with indication of two step  liver surgery.\n\n          7. Patients already included in the study.\n\n          8. Patient who couldn't be treated or followed up according to study criteria for\n             psychological, social, family or geographical reasons. Patient deprived of liberty or\n             under guardianship."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "57", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01880554", 
            "org_study_id": "IB2010-29"
        }, 
        "intervention": {
            "arm_group_label": "Contrast-enhanced intraoperative ultrasound", 
            "description": "Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:\nStep # 1 preoperative (maximum 6 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages", 
            "intervention_name": "Contrast-enhanced intraoperative ultrasound", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Liver metastases", 
            "Colorectal primary cancer", 
            "Contrast-enhanced ultrasound", 
            "Sonovue\u00ae"
        ], 
        "lastchanged_date": "June 14, 2013", 
        "link": {
            "description": "Site internet du promoteur, l'Institut Bergoni\u00e9", 
            "url": "http://www.bergonie.org/fr/essais-clinique.html"
        }, 
        "location": [
            {
                "contact": {
                    "email": "s.evrard@bordeaux.unicancer.fr", 
                    "last_name": "EVRARD SERGE, PU-PH"
                }, 
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "state": "Aquitaine", 
                        "zip": "33000"
                    }, 
                    "name": "Institut Bergoni\u00e9"
                }, 
                "investigator": {
                    "last_name": "EVRARD SERGE, PU-PH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "RIVOIRE Michel, PU-PH"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "state": "Rh\u00f4ne-Alpes", 
                        "zip": "69000"
                    }, 
                    "name": "Centre L\u00e9on B\u00e9rard"
                }, 
                "investigator": {
                    "last_name": "RIVOIRE Michel, PU-PH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Utility of Contrast-enhanced Intraoperative Ultrasound in Surgery of Colorectal Liver Metastases. Phase II Clinical Trial.", 
        "overall_contact": {
            "email": "s.evrard@bordeaux.unicancer.fr", 
            "last_name": "EVRARD SERGE, PU-PH", 
            "phone": "0556333333"
        }, 
        "overall_contact_backup": {
            "email": "s.mathoulin@bordeaux.unicancer.fr", 
            "last_name": "MATHOULIN PELISSIER Simone, PU-PH", 
            "phone": "0556333333"
        }, 
        "overall_official": {
            "affiliation": "Institut Bergoni\u00e9", 
            "last_name": "EVRARD Serge, PU-PH", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France : Agence Fran\u00e7aise de S\u00e9curit\u00e9 Sanitaire des Produits de Sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "For each patient, we will consider that CEUS intraoperative clinical utility:\nif the planned surgery after contrast echocardiography is different from the intraoperative considered after surgery for conventional ultrasound,\nif the planned surgery after contrast echocardiography Intraoperative warranted.", 
            "measure": "The clinical utility will be evaluated in terms of the proposed amendment justified after ultrasound surgery of Intraoperative contrast, compared to the planned following surgery a conventional intraoperative ultrasonography", 
            "safety_issue": "No", 
            "time_frame": "at time of surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01880554"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "evaluation of the clinical utility of contrast echocardiography by subgroups depending on the pre-operative treatment and according to the response to treatment.", 
                "measure": "evaluation of the clinical utility of contrast echocardiography", 
                "safety_issue": "No", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "Assessment of tumor perfusion quantification by software specifically, in the general population and sub-groups according to the type preoperative treatment and depending on the response to treatment.", 
                "measure": "Assessment of tumor perfusion quantification", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Detection rate of liver metastases (equivalent to \"Sensitivity injury\"): number of true liver metastases detected by intraoperative ultrasound / contrast total real liver metastases. Upon discovery of a new lesion typically benign, no gesture will be made. The radiological monitoring at 3 months will confirm or not the presence and nature of the lesion.\nRate characterization of focal liver lesions: number of lesions whose nature was correctly defined by ultrasound Intraoperative contrast (benign and malignant) / total lesions detected by intraoperative ultrasound contrast.", 
                "measure": "Performance Evaluation of intraoperative ultrasound contrast per lesion", 
                "safety_issue": "No", 
                "time_frame": "follow up 3 months"
            }, 
            {
                "description": "Description of technical arrangements for the CEUS intraoperative duration, number of injections and doses necessary time required between two injections, technical limitations.\nDescription de la toxicit\u00e9 sp\u00e9cifique de l'utilisation perop\u00e9ratoire de SonoVue\u00ae, selon l'\u00e9chelle de toxicit\u00e9 NCI-CTC-AE version 4.", 
                "measure": "Description of technical arrangements for the CEUS Intraoperative and description of the specific toxicity of intraoperative use of SonoVue \u00ae,", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "overall survival, defined as the time from the date of surgery and date of death (regardless of cause).\nprogression-free survival, defined as the time from the date of surgery and the date of the first of the following events: progression (RECIST v1.1) or death (whatever the cause).", 
                "measure": "Survival rate", 
                "safety_issue": "No", 
                "time_frame": "followed up to 5 years"
            }
        ], 
        "source": "Institut Bergoni\u00e9", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut Bergoni\u00e9", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "June 2011"
    }
}